Seltavir 75mg 10 capsules — Made in India — Free Delivery

Product description

Seltavir capsules are used for the following indications:

• influenza treatment: the preparation is indicated for adults and children from one year of age who have symptoms of influenza during the circulation of the influenza virus (effectiveness was demonstrated when treatment was started within 2 days after the first onset of symptoms);

flu prevention:

• prevention of influenza in adults and children over one year of age after contact with a person with clinically diagnosed influenza during the circulation of the influenza virus;
• the appropriate use of the preparation for the prevention of influenza must be determined on a case-by-case basis, taking into account the circumstances and taking into account the group of patients who need protection; in exceptional situations (for example, in the event of a disagreement between the circulating influenza virus and the influenza virus against which vaccination was carried out, and during a pandemic) seasonal prophylaxis can be carried out in persons aged one year or older.

Structure

The active ingredient is oseltamivir (one solid capsule contains oseltamivir phosphate equivalent to oseltamivir 75 mg).

Excipients: pregelatinized starch, talc, povidone, sodium croscarmellose, sodium stearyl fumarate, hard gelatin capsule No. 2.

The composition of the capsule: iron oxide red (E172), iron oxide yellow (E172), iron oxide black (E172), titanium dioxide (E 171), gelatin, purified water.

Contraindications

Hypersensitivity to oseltamivir phosphate or to any component of the preparation.

Mode of application

For oral administration.

Adults and adolescents over the age of 13

Treatment. The recommended dosage regimen is one 75 mg capsule 2 times a day for 5 days for adults and adolescents (≥ 13 - <18 years) weighing more than 40 kg. Treatment should be started on the first or second day of the onset of flu symptoms.

Post-exposure prophylaxis. The recommended dose for the prevention of influenza after contact with a sick influenza is 75 mg once a day for 10 days for adults and adolescents (≥ 13 - <18 years) weighing more than 40 kg. The preparation should be taken no later than the first 2 days after contact.

Prevention during a seasonal flu epidemic. The recommended dose for prophylaxis during a seasonal flu epidemic is 75 mg 1 time per day for 6 weeks.

Children ≥ 1 - <13 years of age.

Treatment. The recommended dosage regimen of the preparation with correction of body weight for the treatment of infants and children aged one year and older (recommended dose for 5 days):

from 10 kg to 15 kg - 30 mg 2 times a day;

> 15 kg to 23 kg - 45 mg 2 times a day;

> 23 kg to 40 kg - 60 mg 2 times a day;

> 40 kg - 75 mg 2 times a day.

Treatment should be started as soon as possible on the first or second day of the onset of flu symptoms.

Post-exposure prophylaxis. Recommended dosing regimen (recommended dose for 10 days):

from 10 kg to 15 kg - 30 mg once a day;

> 15 kg to 23 kg - 45 mg once a day;

> 23 kg to 40 kg - 60 mg once a day;

> 40 kg - 75 mg once a day.

Prevention during a seasonal flu epidemic. Prophylaxis during a seasonal flu epidemic in children under 12 years of age has not been investigated.

Application features

Pregnant

Pregnant women can use the preparation taking into account the available safety information, the pathogenicity of the circulating influenza virus and the condition of the pregnant woman after assessing the benefit / risk ratio.

There is limited information on breastfeeding in women taking oseltamivir and on the excretion of oseltamivir in breast milk. Limited data indicate that oseltamivir and its active metabolite were found in breast milk, but levels were low, which could lead to a subtherapeutic dose in the infant. Considering these data, as well as the pathogenicity of the circulating strain of influenza virus and the condition of the woman who is breastfeeding, the question of prescribing oseltamivir may be considered after assessing the benefit / risk ratio.

On the basis of preclinical data, there is no evidence of the effect of the preparation on fertility in men or women.

Drivers

The preparation does not affect the reaction rate when driving or using other mechanisms.

Overdose

Overdose reports were received during clinical trials and during post-marketing use of the preparation. In most of the recorded cases of overdose, no adverse reactions were reported.

The adverse reactions reported in overdose were similar in nature and type to those observed with therapeutic doses of the preparation.

There is no specific antidote.

Overdose has been reported more frequently in children than in adults and adolescents. Caution should be exercised when using the preparation in children.

Side effects

In adults / adolescents, when taking the preparation for the treatment of influenza, frequent adverse events were nausea and vomiting, for the prevention of influenza - nausea. They were transient and usually appeared on the first or second day of treatment and disappeared after 1-2 days. Vomiting was the most common adverse event in children. In most cases, adverse reactions did not lead to discontinuation of the preparation.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 2 years.